CN108853184B - 一种青钱柳和多穗柯提取物组合 - Google Patents
一种青钱柳和多穗柯提取物组合 Download PDFInfo
- Publication number
- CN108853184B CN108853184B CN201811015677.7A CN201811015677A CN108853184B CN 108853184 B CN108853184 B CN 108853184B CN 201811015677 A CN201811015677 A CN 201811015677A CN 108853184 B CN108853184 B CN 108853184B
- Authority
- CN
- China
- Prior art keywords
- extract
- cyclocarya paliurus
- lithocarpus polystachyus
- polystachyus rehd
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 241000233779 Cyclocarya paliurus Species 0.000 title claims abstract description 65
- 241001633106 Lithocarpus Species 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000002904 solvent Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000001603 reducing effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000010030 glucose lowering effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241001122767 Theaceae Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 241000233778 Cyclocarya Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种青钱柳和多穗柯提取物组合,通过对提取方法和组合比例的研究,将青钱柳和多穗柯的提取物进行组合,获得最佳降糖作用的组合物,相比单味提取物,本发明所述的青钱柳和多穗柯的提取物组合降糖活性显著提高,剂量和毒副作用明显降低,极大地提高了治疗效果。
Description
技术领域
本发明属于医药领域,具体涉及一种青钱柳和多穗柯提取物组合。
技术背景
糖尿病是一种以高血糖为特征的代谢病,分为I型糖尿病和II型糖尿病,其中90%以上为II型糖尿病。随着我国社会的进步、经济的发展、人们工作生活方式的改变,我糖尿病的发病率逐年提高,目前全国有糖尿病患者9000多万,还有超过1.4亿的糖尿病前期患者,严重影响患者的生活质量,同时糖尿病还会引发心脏、肾、神经等多器官组织的并发症,危及患者生命。II型糖尿病的治疗困难较大,往往需要长期用药,目前西药和中药两种治疗手段,西药治疗虽然起效快,但副作用大,效果不理想。中药虽然起效慢,但由于是多种成分的组合,往往几种成分的作用机制不同,存在协同增效作用,从宏观、系统的层面上治疗,往往能取得良好的治疗效果。
青钱柳有较好的降血糖作用,其所含的黄酮、多糖和三萜对降糖有重要贡献,但对青钱柳的开发仍处于低层次的农产品阶段,主要是各种青钱柳茶。然而青钱柳单味药的降血糖作用和治疗II型糖尿病的效果有限,只适合于预防和辅助治疗。
发明内容
本发明针对单味青钱柳或多穗柯产品单一、治疗效果不够理想等方面的不足,基于药物之间的相互作用与协同增效原理,将青钱柳提取物与同样具有降糖作用的多穗柯提取物进行复配,获得了具有协同降糖作用的组合物,对更好的利用青钱柳和多穗柯资源,开发新型治疗II型糖尿病的产品具有重要的意义。
本发明的技术方案如下:
一种青钱柳和多穗柯提取物组合,所述青钱柳提取物和多穗柯提取物的质量比为3-0.3:1,所述青钱柳提取物和多穗柯提取物分别为青钱柳干叶和多穗柯干叶的溶剂热提物。
上述青钱柳干叶和多穗柯干叶的溶剂热提物为青钱柳干叶和多穗柯干叶分别在溶剂存在下加热浸提,过滤,合并滤液,减压蒸馏,干燥,获得的青钱柳提取物浸膏和多穗柯提取物浸膏。
优选的,上述提取物组合中青钱柳提取物和多穗柯提取物的质量比为3-0.3:1,更优选为1.6:1。
优选的,所述溶剂选自水、乙醇、乙酸乙酯、丙酮中的一种或几种,更优选为乙醇-水的混合溶剂,进一步的,所述青钱柳提取物采用乙醇浓度为50%的乙醇-水的混合溶剂,所述多穗柯提取物采用乙醇浓度为60%的乙醇-水的混合溶剂。
优选的,上述提取物的制备过程中,青钱柳干叶或多穗柯干叶与溶剂的质量体积之比为1:10-30,更优选的,青钱柳干叶与溶剂的质量体积之比为1:25,所述多穗柯干叶与溶剂的质量体积之比1:20(g/ml)。
优选的,上述提取物的制备过程中,青钱柳干叶和多穗柯干叶分别在溶剂中40-90℃浸提2-24h。
本发明另一目的在于提供本发明所述的青钱柳和多穗柯提取物组合在制备降血糖药物中的应用。
本发明另一目的在于提供一种药物组合物,含有本发明所述的青钱柳和多穗柯提取物组合。
一个具体的操作为:青钱柳干叶或多穗柯干叶在45℃下干燥2-5h,粉碎,过20目筛,每克青钱柳或多穗柯叶粉加溶剂10-30mL,在搅拌下升温至40-90℃,并在该温度下搅拌2-24h,过滤,滤渣继续提取2次,合并滤液,减压蒸去溶剂,真空干燥,得褐色半固态的青钱柳提取物浸膏(Ⅰ)或多穗柯提取物浸膏(Ⅱ)。
将上述青钱柳提取物浸膏(Ⅰ)、多穗柯提取物浸膏(Ⅱ)溶于一定量的蒸馏水中,以糖尿病模型小鼠为实验动物,以上述提取物喂养小鼠2周,以等量蒸馏水喂养的小鼠作为对照组,测定对照组和药物组小鼠的血糖值。优选的,青钱柳提取物浸膏(Ⅰ)和多穗柯提取物浸膏(Ⅱ)的质量之比为(3-0.3):1,更优的配比为1.6:1,剂量可低至100mg·kg-1·d-1,降糖率可以达到99%,增效系数可以达到6.782。
本发明优点:
本发明分别以青钱柳和多穗柯为原料,通过溶剂提取,得到青钱柳和多穗柯提取物组合,发现该组合具有显著降糖增效作用,青钱柳提取物和多穗柯提取物的质量之比为1.6:1时,提取物组合的增效系数接近7,剂量在低至100mg·kg-1·d-1的情况下,降糖率仍可达到99%,相比茶饮产品,降糖活性和治疗效果大大提高,剂量大大降低,具有准确的剂量和良好的预后效果,同时,大大降低原料的消耗,降低了生产成本。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。
在本发明中使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例并参照数据进一步详细描述本发明,应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
本发明以青钱柳、多穗柯降糖成分的提取和活性评价为例进一步详细说明本发明,但应注意本发明的范围并不受这些实施例的任何限制。
实施例1:青钱柳提取物的制备
将100克青钱柳干叶在46℃下干燥3h,粉碎,过20目筛,按照下表的条件分别选取不同的溶剂,以及料液比、提取温度和提取时间,在搅拌下提取,过滤,滤渣用上法再提取2次,合并滤液,减压蒸去溶剂,真空干燥,得褐色半固态的青钱柳提取物浸膏(Ⅰ),计算提取率,研究结果见表1,提取率按下式计算:
表1不同提取条件下青钱柳提取物的提取率。
注:料液比为质量体积比,*表示乙醇浓度,相应的料液比为1:25。
从表中可以看出:乙醇-水混合溶剂对提取有利,具有较高的提取率,当乙醇浓度为60%,料液质量体积比为1:25,提取温度为60℃时,提取时间为6h,提取率可以达到8.6%;乙酸乙酯等溶剂对提取不利。在上述研究的基础上,继续以乙醇-水为溶剂,对上述较优条件的一定范围内的条件,包括料液比做了进一步优化,得到如下最佳提取条件:
将100克青钱柳干叶在46℃下干燥3h,粉碎,过20目筛,以50%的乙醇水溶液为提取剂,每克青钱柳叶粉加溶剂25mL,在搅拌下升温至70℃,继续提取6h,过滤,滤渣用上法再提取2次,合并滤液,减压蒸去溶剂,真空干燥,得褐色半固态的青钱柳提取物浸膏(Ⅰ)10.6克,提取率为10.6%。
实施例2多穗柯提取物的制备
参考实施例1的方法,对多穗柯提取物的提取条件进行了探索,获得了最佳的提取条件如下:
乙醇-水混合溶剂是最佳提取溶剂,乙醇浓度为60%,料液质量体积比为1:20,提取温度为60℃时,提取时间为8h,得褐色半固态的多穗柯提取物浸膏(Ⅱ),提取率为11.4%。
实施例3青钱柳和多穗柯混合叶提取物的制备
青钱柳或多穗柯干叶在45℃下干燥2-5h,将干燥后的青钱柳或多穗柯干叶按质量比为3:1进行混合,粉碎,过20目筛,每克青钱柳和多穗柯叶干粉加乙醇-水混合溶剂30mL,在搅拌下升温至65℃,并在该温度下搅拌6h,过滤,滤渣继续提取2次,合并滤液,减压蒸去溶剂,真空干燥,得褐色半固态青钱柳和多穗柯组合物浸膏(Ⅲ),提取率为9.8%。
实施例4:提取物降糖活性测定
以昆明种小鼠为实验动物,用注射四氧嘧啶溶液造小鼠,将糖尿病小鼠随机分为糖尿病模型对照组、给药组,给药组分高、中、低三个剂量组,每组大约12只,另取同批次的12只未造模小鼠作为正常对照组,给药组分为青钱柳提取物(Ⅰ),多穗柯提取物(Ⅱ)和青钱柳和多穗柯混合叶提取物(Ⅲ)以及青钱柳-多穗柯提取物(Ⅰ+Ⅱ)。高、中和低剂量组分别按提取物500、350、200mg·kg-1·d-1的剂量给药,用时配成等体积不同浓度水溶液(每10g小鼠灌胃0.1mL),每天上午空腹给药1次,连续灌胃15天,模型对照组和正常对照组给等量生理盐水,采用尾静脉取血法采样,采样前禁食不禁水12h。采用葡萄糖氧化酶—过氧化物酶法测定血糖,按照血糖试剂盒中说明书操作,溶液显色后,在505nm处测量吸光度,根据标准曲线计算血糖值,按下述公式计算提取物的降糖率:
其中增效系数按如下公式进行计算:
其中的预计降糖率按如下公式进行计算:
预计降糖率=提取物A的降糖率×A的含量+提取物B的降糖率×B的含量各提取物的降糖效果如表2所示。
表2提取物的降糖率与组合物的协同增效作用。
注:上述提取物均为最佳提取条件下的提取物。
从表2可以看出,将青钱柳和多穗柯叶混合后提取,虽然具有较好的降糖作用,但是协同增效作用不明显,甚至少数混合比例有减效作用,而青钱柳提取物和多穗柯提取物形成的组合物,在所有比例下都表现出一定的协同增效作用。
表2中青钱柳提取物和多穗柯提取物的组合物,当配比为2:1时,增效系数最高达到1.168,也就是活性是预测值的2倍多。因此,在上述研究的基础上,对青钱柳提取物和多穗柯提取物的组合物配比在3:1和1:1间进行优化,剂量在200mg·kg-1·d-1和50mg·kg-1·d-1之间进行优化,优化的结果:青钱柳提取物和多穗柯提取物的组合物配比为1.6:1,剂量为100mg·kg-1·d-1时,降糖率可以达到99%,增效系数可以达到6.782。
Claims (5)
1. 一种青钱柳和多穗柯提取物组合,其特征在于所述青钱柳提取物和多穗柯提取物的质量比为1.6:1,提取物组合的给药剂量为100 mg·kg-1·d-1,所述青钱柳提取物和多穗柯提取物分别为青钱柳干叶和多穗柯干叶的溶剂热提物,所述青钱柳提取物采用乙醇浓度为50%的乙醇-水的混合溶剂40~90℃浸提2~24h,所述多穗柯提取物采用乙醇浓度为60%的乙醇-水的混合溶剂40~90℃浸提2~24h。
2.如权利要求1所述的提取物组合,其特征在于所述青钱柳干叶或多穗柯干叶与溶剂的质量体积之比1:10-30。
3. 如权利要求 2所述的提取物组合,其特征在于所述青钱柳干叶与溶剂的质量体积之比为1:25,所述多穗柯干叶与溶剂的质量体积之比1:20。
4.如权利要求1-3任一项所述的青钱柳和多穗柯提取物组合在制备降血糖药物中的应用。
5.一种药物组合物,其特征在于含有如权利要求 1-3任一项所述的青钱柳和多穗柯提取物组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811015677.7A CN108853184B (zh) | 2018-08-31 | 2018-08-31 | 一种青钱柳和多穗柯提取物组合 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811015677.7A CN108853184B (zh) | 2018-08-31 | 2018-08-31 | 一种青钱柳和多穗柯提取物组合 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108853184A CN108853184A (zh) | 2018-11-23 |
CN108853184B true CN108853184B (zh) | 2021-04-13 |
Family
ID=64322687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811015677.7A Active CN108853184B (zh) | 2018-08-31 | 2018-08-31 | 一种青钱柳和多穗柯提取物组合 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108853184B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339229B (zh) * | 2019-08-14 | 2021-09-21 | 广西壮族自治区中医药研究院 | 一种降黏清血组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412222A (zh) * | 2015-12-22 | 2016-03-23 | 桂林双象生物科技有限公司 | 甜茶和青钱柳的复合原茶的制备方法 |
CN106963807A (zh) * | 2017-04-21 | 2017-07-21 | 皖南医学院 | 一种降血糖口服液及其制备方法 |
CN107412341A (zh) * | 2017-04-17 | 2017-12-01 | 中国药科大学 | 一种含青钱柳的降糖配方及其制备方法 |
CN108324803A (zh) * | 2018-03-23 | 2018-07-27 | 深圳市太空科技南方研究院 | 辅助降血糖的固体饮料及其制备方法 |
-
2018
- 2018-08-31 CN CN201811015677.7A patent/CN108853184B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412222A (zh) * | 2015-12-22 | 2016-03-23 | 桂林双象生物科技有限公司 | 甜茶和青钱柳的复合原茶的制备方法 |
CN107412341A (zh) * | 2017-04-17 | 2017-12-01 | 中国药科大学 | 一种含青钱柳的降糖配方及其制备方法 |
CN106963807A (zh) * | 2017-04-21 | 2017-07-21 | 皖南医学院 | 一种降血糖口服液及其制备方法 |
CN108324803A (zh) * | 2018-03-23 | 2018-07-27 | 深圳市太空科技南方研究院 | 辅助降血糖的固体饮料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
多穗柯不同液相提取物对糖尿病小鼠MDA_CAT活性的影响;张俭;《湖北农业科学》;20120131;第51卷(第2期);第354页左栏最后1段及右栏最后1段、第355页左栏第1-2段、倒数第1-2段及右栏第1段、第357页左栏最后1段及右栏第1段 * |
多穗柯总黄酮的降糖作用;韦宝伟等;《内科》;20080825;第3卷(第04期);第510-512页 * |
青钱柳提取物对家兔实验性糖尿病模型降血糖作用的研究;上官新晨等;《西北农林科技大学学报(自然科学版)》;20031225;第31卷(第06期);第117页摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN108853184A (zh) | 2018-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102038720B (zh) | 一种桦褐孔菌降血糖有效部位及其制备方法与应用 | |
CN103980261B (zh) | 卡格列净的a晶型及其结晶制备方法 | |
CN102178741A (zh) | 具有降血糖作用的番石榴叶提取物及其制备方法与应用 | |
CN103070880A (zh) | 白簕多糖在制备治疗糖尿病药物中的应用 | |
CN106220701B (zh) | 三萜化合物及其制备方法与应用 | |
CN108853184B (zh) | 一种青钱柳和多穗柯提取物组合 | |
CN109232757B (zh) | 核桃叶多糖提取物及应用 | |
CN101095720B (zh) | 一种丹参总酚酸的制备方法及其在制备药物中的应用 | |
CN112778260A (zh) | 一种蓝莓富花青素提取物及其制备方法 | |
CN112741851A (zh) | 低共熔溶剂法提取雀嘴茶提取物的方法及颗粒剂的制备和应用 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN108743658B (zh) | 一种青钱柳和核桃叶提取物组合 | |
CN105920051B (zh) | 一种金针菇提取物及其制备方法与应用 | |
CN104013669A (zh) | 具有降血糖作用的青钱柳总黄酮的制备方法 | |
CN102670698B (zh) | 千斤拔提取物在制备防治糖尿病药物中的应用 | |
CN108403980B (zh) | 一种降血糖植物提取物有效部位及其制备方法和应用 | |
CN111920799A (zh) | 一种苦乐果有效成分组合物及其制备方法和应用 | |
CN112716988A (zh) | 倒心盾翅藤提取物在制备预防和/或治疗糖尿病肾病的药物中的应用 | |
CN107513092B (zh) | 一种丙二酰基人参皂苷Rb1的制备方法及其医用用途 | |
CN112641816A (zh) | 一种含菊芋提取物的组合物及其在ⅱ型糖尿病及并发症中的应用 | |
CN101167887A (zh) | 口服治疗糖尿病肾病的枸杞单方中药及其制备方法 | |
CN107126450B (zh) | 鼠麹草提取物、鼠麹草有效物质富集物,制备方法与应用 | |
CN109172667A (zh) | 一种瓯柑果实富含多甲氧基黄酮组分提取物的降糖用途 | |
CN1095669C (zh) | 含原人参二醇组分皂甙的药物组合物,其制备方法及应用 | |
CN103800389A (zh) | 一种Sarcodon leucopus中降糖活性成分及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20181123 Assignee: Hunan Fenghuang lance traditional Chinese Medicine Co.,Ltd. Assignor: JISHOU University Contract record no.: X2023980045927 Denomination of invention: A combination of extracts from Cyclocarya paliurus and Polygonatum multiflorum Granted publication date: 20210413 License type: Exclusive License Record date: 20231108 |
|
EE01 | Entry into force of recordation of patent licensing contract |